Vaccines & Biodefense

Webinar recorded on June 30, 2022, and moderated by Phyllis Arthur, Vice President, Infectious Disease and Emerging Science Policy, BIO.  Webinar slides are available at this link.

The US Government invests in biomedical research in many ways, including direct funding of some critical R&D areas for diagnostics, vaccines, and therapeutics that could strengthen biodefense preparedness. This three-part webinar details for the biotechnology corporate and academic community the many new and previously available sources of capital, as well as the processes for applying for funding, from the US Department of Defense.

The Department of Defense (DoD) is continuously engaging in efforts to protect the warfighter from a broad array of threats. Preparing for and responding to these threats requires key partnerships with the industry to develop vaccines, therapeutics, and diagnostics that are designed specifically to meet the unique needs of the warfighter in various situations. Many of the investments made through these partnerships also support broader applications of key biotechnologies for other unmet healthcare needs. This important webinar represents an opportunity for BIO members and the whole biotechnology community to get an update about the priorities and programs within the DoD and the ways companies can work with the Agency on their priorities.

Part 1—Opening Remarks on DoD Priorities and Investing at the Speed of Need: Novel Technologies and Platforms to Accelerate Drug Development (60 minutes)

Part 2—Repurposing and Redirecting: An Alternate Approach to Accelerating Medical Countermeasures (42 minutes)

Part 3—How to Work with DoD (16 minutes)